Asymptomatic screening for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) as an infection prevention measure in healthcare facilities: Challenges and considerations

Abstract

Executive summary Testing of asymptomatic patients for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) (ie, “asymptomatic screening) to attempt to reduce the risk of nosocomial transmission has been extensive and resource intensive, and such testing is of unclear benefit when added to other layers of infection prevention mitigation controls. In addition, the logistic challenges and costs related to screening program implementation, data noting the lack of substantial aerosol generation with elective controlled intubation, extubation, and other procedures, and the adverse patient and facility consequences of asymptomatic screening call into question the utility of this infection prevention intervention. Consequently, the Society for Healthcare Epidemiology of America (SHEA) recommends against routine universal use of asymptomatic screening for SARS-CoV-2 in healthcare facilities. Specifically, preprocedure asymptomatic screening is unlikely to provide incremental benefit in preventing SARS-CoV-2 transmission in the procedural and perioperative environment when other infection prevention strategies are in place, and it should not be considered a requirement for all patients. Admission screening may be beneficial during times of increased virus transmission in some settings where other layers of controls are limited (eg, behavioral health, congregate care, or shared patient rooms), but widespread routine use of admission asymptomatic screening is not recommended over strengthening other infection prevention controls. In this commentary, we outline the challenges surrounding the use of asymptomatic screening, including logistics and costs of implementing a screening program, and adverse patient and facility consequences. We review data pertaining to the lack of substantial aerosol generation during elective controlled intubation, extubation, and other procedures, and we provide guidance for when asymptomatic screening for SARS-CoV-2 may be considered in a limited scope.

Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)

“…Reinforcing of existing levels of protection (e.g. switching to universal use of N95 respirators when performing certain procedures on any patient, active versus passive screening of healthcare workers for signs of COVID-19) seems to be a more practical and reasonable approach [ 97 ].…”

Best Practices and a Business Case for Surgical Site Infection Prevention

“…Throughout the pandemic, organization leaders modified hospital policies for preventing perioperative transmission of COVID‐19 based on epidemiology. The Society for Healthcare Epidemiology of America does not recommend routine, universal asymptomatic screening for SARS‐CoV‐2 (the virus that causes COVID‐19) 54 . Rather, facility leaders should consider community incidence and transmission of COVID‐19, the patient population, facility layout, and procedures that may increase transmission in the health care environment when implementing asymptomatic screening.…”

Patient and ward related risk factors in a multi-ward nosocomial outbreak of COVID-19: Outbreak investigation and matched case–control study

“…Information on HCWs was insufficient to include in the study. Although we did not employ universal admission RT-PCR testing for SARS-CoV-2 as per local policy, recent recommendations argue against its routine use for asymptomatic persons in healthcare facilities[51].…”